Adenoid cystic carcinoma: A retrospective clinical review

被引:193
作者
Khan, AJ
DiGiovanna, MP
Ross, DA
Sasaki, CT
Carter, D
Son, YH
Haffty, BG
机构
[1] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA
[3] Yale Univ, Sch Med, Dept Surg Otolaryngol, New Haven, CT 06520 USA
[4] Yale Univ, Sch Med, Dept Med Med Oncol, New Haven, CT 06520 USA
关键词
adenoid cystic carcinoma; head and neck cancer; radiation therapy; HER-2; neu;
D O I
10.1002/ijc.1013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Adenoid cystic carcinoma (ACC) are uncommon tumors, representing about 10% to 15% of head and neck tumors. We compare the survival and control rates at our institution with those reported in the literature, and examine putative predictors of outcome. All patients registered with the tumor registry as having had ACC were identified. Demographic and survival variables were retrieved from the database. Additionally, a chart review of all patients was done to obtain specific information. Minor gland tumors were staged using the American Joint Committee on Cancer's criteria for squamous cell carcinomas in identical sites. Histopathologic variables retrieved included grade of the tumor, margins, and perineural invasion. Treatment modalities, field sizes, and radiation doses were recorded in applicable cases. An effort to retrieve archival tumor specimens for immunohistochemical analysis was undertaken. A total of 69 patients were treated for ACC from 1955 to 1999. One patient, who presented with fatal brain metastasis, was excluded from further analysis. Of the remaining 68 patients, 30 were men and 38 were women. The average age at diagnosis was 52 years, and mean follow-up was 13.2 years. Mean survival was 7.7 years. Overall survival (OS) rates at 5, 10, and 15 years were 72%, 44%, and 34%, and cause-specific survival was 83%, 71%, and 55%, respectively. Recurrence-free survival rates were 65%, 52%, and 30% at 5, 10, and 15 years, with a total of 29 of 68 (43%) eventually suffering a recurrence. Overall survival was adversely affected by advancing T and AJCC stage. Higher tumor grades were also associated with decreased OS, although the numbers compared were small. Primaries of the nasosinal region fared poorly when compared with other locations. Total recurrence-free survival, local and distant recurrence rates were distinctly better in primaries of the oral cavity/oropharynx when compared with those in other locations. Reduced distant recurrence-free survival was' significantly associated with increasing stage. No other variables were predictive for recurrence. Additionally, we found that nasosinal tumors were more likely to display higher stage at presentation, and were more often associated with perineural invasion. Also of interest was the association of perineural invasion with margin status, with 15 of 20 patients with positive margins displaying perineural invasion, while only 5 of 17 with negative margins showed nerve invasion (P = 0.02). On immunohistochemistry, 2 cases of the 29 (7%) tumor specimens found displayed HER-2/neu positivity. No correlation between clinical behavior and positive staining could be demonstrated. Our data concur with previous reports on ACC in terms of survival and recurrence statistics. Stage and site of primary were important determinants of outcome. Grade may still sen e a role in decision making. We could not demonstrate any differences attributable to primary modality of therapy, perhaps due to the nonrandomization of patients into the various treatment tracks and the inclusion of palliative cases. Similarly, perineural invasion, radiation dose and field size, and HER-Z/neu positivity did not prove to be important factors in our experience. (C) 2001 Wiley-Liss, Inc.
引用
收藏
页码:149 / 158
页数:10
相关论文
共 30 条
[1]  
*AM JOINT COMM CAN, 1992, MAN STAG CANC
[2]  
Cho KJ, 1999, HEAD NECK-J SCI SPEC, V21, P414
[3]   Neutron radiotherapy for adenoid cystic carcinoma of minor salivary glands [J].
Douglas, JG ;
Laramore, GE ;
AustinSeymour, M ;
Koh, WJ ;
Lindsley, KL ;
Cho, P ;
Griffin, TW .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 36 (01) :87-93
[4]   THE INFLUENCE OF POSITIVE MARGINS AND NERVE INVASION IN ADENOID CYSTIC CARCINOMA OF THE HEAD AND NECK TREATED WITH SURGERY AND RADIATION [J].
GARDEN, AS ;
WEBER, RS ;
MORRISON, WH ;
ANG, KK ;
PETERS, LJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 32 (03) :619-626
[5]  
Gates G A, 1972, Otolaryngol Clin North Am, V5, P283
[6]   C-ERBB-2/NEU ONCOGENE AND KI-67 ANALYSIS IN THE ASSESSMENT OF PALATAL SALIVARY-GLAND NEOPLASMS [J].
GIANNONI, C ;
ELNAGGAR, AK ;
ORDONEZ, NG ;
TU, ZN ;
AUSTIN, J ;
LUNA, MA ;
BATSAKIS, JG .
OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 1995, 112 (03) :391-398
[7]   EXPRESSION OF C-ERBB-2 ONCOPROTEIN IN SALIVARY-GLAND TUMORS - AN IMMUNOHISTOCHEMICAL STUDY [J].
KERNOHAN, NM ;
BLESSING, K ;
KING, G ;
CORBETT, IP ;
MILLER, ID .
JOURNAL OF PATHOLOGY, 1991, 163 (01) :77-80
[8]   NEUTRON VERSUS PHOTON IRRADIATION FOR UNRESECTABLE SALIVARY-GLAND TUMORS - FINAL REPORT OF AN RTOG-MRC RANDOMIZED CLINICAL-TRIAL [J].
LARAMORE, GE ;
KRALL, JM ;
GRIFFIN, TW ;
DUNCAN, W ;
RICHTER, MP ;
SAROJA, KR ;
MAOR, MH ;
DAVIS, LW .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1993, 27 (02) :235-240
[9]  
MATSUBA HM, 1986, CANCER, V57, P519, DOI 10.1002/1097-0142(19860201)57:3<519::AID-CNCR2820570319>3.0.CO
[10]  
2-V